Nova-Eye Medical Limited (ASX:EYE) has disclosed that director Thomas George Duthy acquired a total of 200,000 ordinary shares through on-market purchases on 6 and 9 November 2026, with the transactions completed via an indirect interest held through CIPA Investments Pty Ltd.

Key Points

  • Director Thomas George Duthy acquired 200,000 ordinary shares across two on-market trades on 6 and 9 November 2026
  • Total consideration paid for all shares acquired was $28,814.71
  • Shares were acquired indirectly through CIPA Investments Pty Ltd <CIPA Investments A/C>
  • Prior to the change, the registered holder held nil ordinary shares in that capacity; following the change, the indirect holding stands at 200,000 shares
  • The trades were not conducted during a closed period requiring prior written clearance

Transaction Details Across Two Trading Dates

According to the filing lodged under ASX Listing Rule 3.19A.2, the acquisition occurred in two tranches. On 6 November 2026, 134,291 ordinary shares were acquired for a total consideration of $18,910.74. A further 65,709 shares were acquired on 9 November 2026 for $9,903.97. The filing notes the date of the last director's interest notice for Thomas George Duthy as 5 November 2026, with the current notice recording the change as of 9 November 2026.

Indirect Interest Held Through CIPA Investments Pty Ltd

The filing discloses that the nature of the director's interest is indirect, with CIPA Investments Pty Ltd operating under the CIPA Investments account as the registered holder. Prior to these transactions, the number of securities held through this vehicle was nil. Following completion of both on-market purchases, the total indirect holding in ordinary shares stands at 200,000. No securities were disposed of as part of these transactions, and no changes to director interests in contracts were recorded.

Closed Period and Clearance Confirmation

The filing states that the interests in securities detailed in the notice were not traded during a closed period in which prior written clearance was required. As such, no written clearance documentation is referenced in the disclosure. The notice was submitted by Nova-Eye Medical Limited as agent for the director pursuant to section 205G of the Corporations Act, in accordance with the company's obligations under ASX listing rules governing changes in director interests.